DrugPatentWatch Database Preview
Drugs in Development Information for TD-4208
» See Plans and Pricing
What is the drug development status for TD-4208?
TD-4208 is an investigational drug.
There have been 13 clinical trials for TD-4208.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Theravance Biopharma R & D, Inc., Theravance Biopharma, and Mylan Inc.
There are thirty-seven US patents protecting this investigational drug and one hundred and twenty-five international patents.
Summary for TD-4208
| US Patents | 37 |
| International Patents | 125 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2015-09-01) |
| Vendors | 27 |
Recent Clinical Trials for TD-4208
| Title | Sponsor | Phase |
|---|---|---|
| A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Subjects With COPD | Mylan Inc. | Phase 3 |
| A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Subjects With COPD | Theravance Biopharma | Phase 3 |
| Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD | Theravance Biopharma R & D, Inc. | Phase 3 |
Clinical Trial Summary for TD-4208
Top disease conditions for TD-4208
Top clinical trial sponsors for TD-4208
US Patents for TD-4208
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TD-4208 | Start Trial | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| TD-4208 | Start Trial | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| TD-4208 | Start Trial | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| TD-4208 | Start Trial | Crystalline freebase forms of a biphenyl compound | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | Start Trial |
| TD-4208 | Start Trial | Biphenyl compounds useful as muscarinic receptor antagonists | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | Start Trial |
| TD-4208 | Start Trial | Crystalline forms of a biphenyl compound | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TD-4208
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TD-4208 | Australia | AU2010273514 | 2029-07-15 | Start Trial |
| TD-4208 | Brazil | BR112012000890 | 2029-07-15 | Start Trial |
| TD-4208 | Canada | CA2765621 | 2029-07-15 | Start Trial |
| TD-4208 | Canada | CA2989129 | 2029-07-15 | Start Trial |
| TD-4208 | China | CN102470130 | 2029-07-15 | Start Trial |
| TD-4208 | Cyprus | CY1117075 | 2029-07-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
